Literature DB >> 16965907

Leukotriene E(4) in urine in patients with asthma and COPD--the effect of smoking habit.

E Gaki1, G Papatheodorou, E Ischaki, V Grammenou, I Papa, S Loukides.   

Abstract

Leukotriene E(4) (LTE(4)) is implicated in asthma pathophysiology and possibly in chronic obstructive pulmonary disease (COPD) as one of the causes of persistent bronchoconstriction and mucus hypersecretion. Cigarette smoking stimulates cysteinyl leukotrienes (CysLTs) production. We investigated whether LTE(4) is equally increased in asthma and COPD and whether smoking significantly affects LTE(4) levels. Secondary outcomes involved correlations with inflammatory and functional parameters. We studied 40 patients with COPD [20 smokers], 40 asthmatics [20 smokers] and 30 healthy subjects [15 smokers]. Spirometry (FEV(1)% pred., FEV(1)/FVC) was performed, urine was collected for measurement of LTE(4) and creatinine, induced sputum was collected for differential cell counts and serum for ECP. LTE(4)/creatinine levels (pg/mg) [mean (sd)] were increased in asthmatic patients compared to COPD and controls, [125.6(54.5) vs. 54.5(19) vs. 55.9(18.9)pg/mg, respectively, P<0.0001 for asthma]. Smoking significantly affects LTE(4) levels only in asthmatic patients [164 (48) vs. 87 (26.3), P<0.0001 for smokers]. The only significant correlation was between eosinophils in induced sputum and LTE(4)/creatinine levels in asthmatics. In conclusion, patients with asthma presented higher LTE(4) values compared to normals and patients with COPD. Smoking significantly affects LTE(4) values only in asthmatics indicating a different underlying CysLTs inflammatory process in this condition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16965907     DOI: 10.1016/j.rmed.2006.06.031

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  7 in total

1.  Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma.

Authors:  Stephen C Lazarus; Vernon M Chinchilli; Nancy J Rollings; Homer A Boushey; Reuben Cherniack; Timothy J Craig; Aaron Deykin; Emily DiMango; James E Fish; Jean G Ford; Elliot Israel; James Kiley; Monica Kraft; Robert F Lemanske; Frank T Leone; Richard J Martin; Gene R Pesola; Stephen P Peters; Christine A Sorkness; Stanley J Szefler; Michael E Wechsler; John V Fahy
Journal:  Am J Respir Crit Care Med       Date:  2007-01-04       Impact factor: 21.405

Review 2.  The adult asthmatic.

Authors:  Amir A Zeki; Nicholas J Kenyon; Ken Yoneda; Samuel Louie
Journal:  Clin Rev Allergy Immunol       Date:  2012-08       Impact factor: 8.667

Review 3.  Asthma and Obstructive Sleep Apnea.

Authors:  Yi-Xian Qiao; Yi Xiao
Journal:  Chin Med J (Engl)       Date:  2015-10-20       Impact factor: 2.628

4.  Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19.

Authors:  Milena Sokolowska; G Enrico Rovati; Zuzana Diamant; Eva Untersmayr; Jürgen Schwarze; Zuzanna Lukasik; Florentina Sava; Alba Angelina; Oscar Palomares; Cezmi A Akdis; Liam O'Mahony; Milos Jesenak; Oliver Pfaar; María José Torres; Marek Sanak; Sven-Erik Dahlén; Grzegorz Woszczek
Journal:  Allergy       Date:  2022-02-25       Impact factor: 14.710

Review 5.  Integrating evidence for managing asthma in patients who smoke.

Authors:  David Price; Leif Bjermer; Todor A Popov; Alison Chisholm
Journal:  Allergy Asthma Immunol Res       Date:  2014-02-17       Impact factor: 5.764

Review 6.  Asthma phenotypes: the intriguing selective intervention with Montelukast.

Authors:  Cottini Marcello; Lombardi Carlo
Journal:  Asthma Res Pract       Date:  2016-08-12

7.  Exposure to volatile organic compounds and airway inflammation.

Authors:  Jae-Woo Kwon; Hee-Won Park; Woo Jin Kim; Man-Goo Kim; Seung-Joon Lee
Journal:  Environ Health       Date:  2018-08-07       Impact factor: 5.984

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.